(S,R,S)-AHPC-Boc-trans-3-aminocyclobutanol-Pip-CH2COOH, also known as VH032-Boc-trans-3-aminocyclobutanol-Pip-CH2COOH, is a conjugate compound comprising a ligand-linker that targets E3 ligase and, on one end, features a VHL ligand. It is employed in PROTAC technology applications.
N-PEG3-N'-(propargyl-PEG4)-Cy5 is a polyethylene glycol (PEG)-derived linker utilized in the fabrication of proteolysis-targeting chimeras (PROTACs)[1].
N-(Boc-PEG3)-N-bis(PEG3-acid) is a polyethylene glycol (PEG)-based linker compound utilized for the synthesis of proteolysis-targeting chimeras (PROTACs)[1].
N-PEG3-N'-(azide-PEG3)-Cy5 (chloride) is a polyethylene glycol (PEG) derivative, commonly known as a PROTAC linker. This compound plays a crucial role in the synthesis of proteolysis targeting chimeras (PROTACs)[1]
PROTAC MDM2 Degrader-3 is a compound that leverages PROTAC technology to degrade MDM2. It consists of a highly effective MDM2 inhibitor, a linker, and the MDM2 ligand for E3 ubiquitin ligase[1].
N-(Amino-PEG3)-N-bis(PEG4-Boc) is a polyethylene glycol (PEG) derivative commonly employed as a linker in the creation of proteolysis targeting chimeras (PROTACs)[1].
N3-PEG3-CH2CH2COOH, a PEG-based PROTAC linker, is utilized in the synthesis of BI-3663, BI-4216, and BI-0319. Additionally, Azido-PEG3-acid, a non-cleavable 3-unit PEG ADC linker, is employed in the synthesis of antibody-drug conjugates (ADCs).
N-(Mal-PEG6)-N-bis(PEG3-amine) is a Polyethylene Glycol (PEG)-based proteolysis targeting chimera (PROTAC) linker, which is utilized for the synthesis of PROTACs[1].
N-(Boc-PEG3)-N-bis(PEG3-azide) is a polyethylene glycol (PEG)-based linker, specifically designed for the synthesis of proteolysis targeting chimeras (PROTACs) [1].
DBCO-(PEG)3-VC-PAB-MMAE is a chemical compound where monomethyl auristatin E (MMAE), a potent tubulin inhibitor acting as a toxin payload in antibody-drug conjugates, is conjugated to a DBCO-(PEG)3-vc-PAB linker.
Biotin-PEG3-(CH2)3-NH2 TFA salt is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.
N-(Acid-PEG2)-N-bis(PEG3-azide) is a polyethylene glycol (PEG)-based linker. It is utilized in the synthesis of proteolysis targeting chimeras (PROTACs), a unique class of molecules designed for targeted protein degradation[1].
N-(Aminooxy-PEG2)-N-bis(PEG3-propargyl) is a polyethylene glycol (PEG) derivative commonly employed as a PEG-based linker in the manufacturing of proteolysis-targeting chimeras (PROTACs)[1].
PROTAC ER Degrader-3, an intermediate for the synthesis of PAC, specifically compound LP2. PAC serves as the linker for ADCs and PROTACs that are conjugated to an antibody. Notably, when PAC is conjugated to an antibody, it exhibits enhanced degradation of estrogen receptor-alpha (ERα) compared to PROTAC alone [1].
Benzyl-N-bis(PEG3-Boc) is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.
Boc-N-Amido-PEG3-azide is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.
DOTA-(t-butyl)3-PEG5-azide is a polyethylene glycol (PEG) derived linker designed specifically for the synthesis of proteolysis targeting chimeras (PROTACs)[1].
K-Ras ligand-Linker Conjugate 3 (Compound 001371) is a chemical compound that consists of a ligand for K-Ras recruiting moiety and a PROTAC linker, responsible for recruiting E3 ligases (e.g., VHL, CRBN, MDM2, and IAP). This compound is essential in the synthesis of PROTAC K-Ras Degrader-1, a potent PROTAC K-Ras degrader that demonstrates a degradation efficacy of ≥70% in SW1573 cells[1].
N3-PEG3-C2-PFP ester is a 3-unit polyethylene glycol (PEG) linker devoid of cleavable bonds. It is commonly employed in the synthesis of antibody-drug conjugates (ADCs).